Accelerate Diagnostics Revenue vs. Number Of Shares Shorted

AXDX Stock  USD 1.70  0.13  8.28%   
Based on Accelerate Diagnostics' profitability indicators, Accelerate Diagnostics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Accelerate Diagnostics' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
1995-09-30
Previous Quarter
M
Current Value
M
Quarterly Volatility
1.1 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Sales General And Administrative To Revenue is likely to rise to 84.40 in 2024, whereas Price To Sales Ratio is likely to drop 3.85 in 2024. At this time, Accelerate Diagnostics' Income Tax Expense is fairly stable compared to the past year. Change To Netincome is likely to rise to about 11.6 M in 2024, despite the fact that Accumulated Other Comprehensive Income is likely to grow to (581.4 K).
For Accelerate Diagnostics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Accelerate Diagnostics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Accelerate Diagnostics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Accelerate Diagnostics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Accelerate Diagnostics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnostics. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.59)
Revenue Per Share
0.665
Quarterly Revenue Growth
0.022
Return On Assets
(0.76)
The market value of Accelerate Diagnostics is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnostics' market value can be influenced by many factors that don't directly affect Accelerate Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Accelerate Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Accelerate Diagnostics Number Of Shares Shorted vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Accelerate Diagnostics's current stock value. Our valuation model uses many indicators to compare Accelerate Diagnostics value to that of its competitors to determine the firm's financial worth.
Accelerate Diagnostics is rated below average in revenue category among its peers. It is rated below average in number of shares shorted category among its peers making about  0.04  of Number Of Shares Shorted per Revenue. The ratio of Revenue to Number Of Shares Shorted for Accelerate Diagnostics is roughly  22.96 . At this time, Accelerate Diagnostics' Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Accelerate Diagnostics' earnings, one of the primary drivers of an investment's value.

Accelerate Revenue vs. Competition

Accelerate Diagnostics is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 6.78 Billion. Accelerate Diagnostics adds roughly 12.06 Million in revenue claiming only tiny portion of equities under Health Care industry.

Accelerate Number Of Shares Shorted vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Accelerate Diagnostics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
12.06 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Accelerate Diagnostics

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
525.17 K
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Accelerate Number Of Shares Shorted Comparison

Accelerate Diagnostics is currently under evaluation in number of shares shorted category among its peers.

Accelerate Diagnostics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Accelerate Diagnostics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Accelerate Diagnostics will eventually generate negative long term returns. The profitability progress is the general direction of Accelerate Diagnostics' change in net profit over the period of time. It can combine multiple indicators of Accelerate Diagnostics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-612 K-581.4 K
Operating Income-54 M-51.3 M
Income Before Tax-60.8 M-57.7 M
Total Other Income Expense Net-6.7 M-6.4 M
Net Loss-61.6 M-58.5 M
Income Tax Expense850 K892.5 K
Net Loss-56.2 M-59.1 M
Net Loss-63.2 M-66.4 M
Non Operating Income Net Other-5.5 M-5.8 M
Interest Income1.3 M1.2 M
Net Interest Income-5.7 M-6 M
Change To Netincome8.3 M11.6 M
Net Loss(4.94)(5.19)
Income Quality 0.65  1.13 
Net Income Per E B T 1.01  0.74 

Accelerate Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Accelerate Diagnostics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Accelerate Diagnostics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Accelerate Diagnostics' important profitability drivers and their relationship over time.

Use Accelerate Diagnostics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Accelerate Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Accelerate Diagnostics will appreciate offsetting losses from the drop in the long position's value.

Accelerate Diagnostics Pair Trading

Accelerate Diagnostics Pair Trading Analysis

The ability to find closely correlated positions to Accelerate Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Accelerate Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Accelerate Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Accelerate Diagnostics to buy it.
The correlation of Accelerate Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Accelerate Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Accelerate Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Accelerate Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Accelerate Diagnostics position

In addition to having Accelerate Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Non-Metallic and Industrial Metal Mining Thematic Idea Now

Non-Metallic and Industrial Metal Mining
Non-Metallic and Industrial Metal Mining Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Non-Metallic and Industrial Metal Mining theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Non-Metallic and Industrial Metal Mining Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.